| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8684003 | Epilepsy Research | 2018 | 20 Pages |
Abstract
Our study suggests that VNS is a generally safe and effective adjunct treatment for CDKL5-associated epilepsy. Additional benefits such as mood and behavioural improvements provide further support of its use in the CDKL5 Deficiency Disorder. Future studies are required to determine the optimal settings and therapeutic potential for this treatment.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Zhan Lim, Kingsley Wong, Jenny Downs, Keely Bebbington, Scott Demarest, Helen Leonard,